Addiction Circuitry in the Human Brain*

Nora D. Volkow,1,2 Gene-Jack Wang,3 Joanna S. Fowler,3 and Dardo Tomasi2

1National Institute on Drug Abuse (NIDA), National Institutes of Health, Bethesda, Maryland 20892; email: nvolkow@nida.nih.gov
2National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institutes of Health, Bethesda, Maryland 20892
3Medical Department, Brookhaven National Laboratory, Upton, New York 11973

Keywords
conditioning, executive function, accumbens, dorsal striatum, orbitofrontal cortex, cingulate gyrus

Abstract
A major challenge in understanding substance-use disorders lies in uncovering why some individuals become addicted when exposed to drugs, whereas others do not. Although genetic, developmental, and environmental factors are recognized as major contributors to a person’s risk of becoming addicted, the neurobiological processes that underlie this vulnerability are still poorly understood. Imaging studies suggest that individual variations in key dopamine-modulated brain circuits, including circuits involved in reward, memory, executive function, and motivation, contribute to some of the differences in addiction vulnerability. A better understanding of the main circuits affected by chronic drug use and the influence of social stressors, developmental trajectories, and genetic background on these circuits is bound to lead to a better understanding of addiction and to more effective strategies for the prevention and treatment of substance-use disorders.
INTRODUCTION

The rewarding effect of drugs of abuse is the main reason why humans use them and laboratory animals self-administer them (1). However, most individuals using drugs never escalate to uncontrollable levels of drug use and only a relatively small percentage does (approximately 10–20%). These are the individuals who fit diagnostic criteria (as per DSM IV) for substance abuse or dependence (compulsive drug use with loss of control over intake despite adverse consequences) (2). Who becomes addicted (term used in lieu of the dependence term used by DSM IV to avoid confusion with physical dependence) and who does not are strongly influenced by genetic (50% of risk), developmental (risk is higher in adolescence than adulthood), and environmental factors (drug access, stress), as well as the type of drug (some drugs produce addiction faster than others, e.g., methamphetamine versus marijuana) (2).

It is generally accepted that the rewarding effects of drugs are due to their ability to increase dopamine (DA) particularly in the nucleus accumbens (NAc) (3). The potency of drugs as well as the mechanism by which they increase DA differs for the various drug classes (4). Interestingly, DA’s role in drug reward (as well as reward in general) does not seem to equate with hedonic pleasure (mediated in part by endogenous opioids and cannabinoids), but instead DA appears to encode prediction of reward, imprinting incentive value to reinforcers (energizing approach behavior) and facilitating learning of reward associations (conditioning) through its modulation of subcortical (including the NAc) and cortical brain regions (reviewed in Reference 5).

Initial work on DA’s role in drug reward focused on the mesolimbic DA pathway—DA neurons in the ventral tegmental area (VTA) projecting into the NAc (1). More recent work now recognizes the crucial role of the mesostriatal (projections from substantia nigra into dorsal striatum) and mesocortical pathways (projections from the VTA into the frontal cortex) in drug reward and addiction (1). DA signals through five different receptors of which the most ubiquitous are the D1 (D1R) and D2 receptors (D2R), which are also the ones that are best understood. The low-affinity D1R is stimulated by large DA increases as induced by phasic DA cell firing and is implicated in drug reward and conditioning. The high-affinity D2R is stimulated by relatively low DA concentrations, as are induced by tonic DA cell firing, and it may interfere with drug reward (6). Differential adaptation in D1R versus D2R signaling pathways with repeated drug administration is likely to underlie neuroplastic changes in addiction. Overall in animal studies, the increases in D1R signaling are associated with sensitized responses to drugs, and the decreases in D2R signaling with compulsive drug intake (7, 8). Neuroplastic changes in D1R- and D2R-modulated pathways are driven in part by modification in the expression of AMPA and NMDA receptors in glutamatergic synapses (9).

Neurotransmitters other than DA (e.g., cannabinoids, opioids) are also involved with drug reward, and their relative contribution to a drug’s rewarding effects is determined in part by their pharmacological effects (e.g., endogenous opioids for heroin, alcohol, nicotine). Similarly, several neurotransmitters are also involved in the neuroadaptations associated with addiction (e.g., decreases in endogenous opioid signaling in cocaine addiction), including the central role of glutamate in the neuroplastic changes associated with chronic drug exposures (10, 11).

Clinical studies have used positron emission tomography (PET) to evaluate DA’s role in drug reward and addiction (and, to a lesser extent, the role of endogenous opioids), whereas fMRI studies have concentrated on delineating the neuronal pathways affected by drugs in addicted subjects. These findings show that addiction affects not only the reward circuit, but also circuits involved with memory (conditioning/habits), motivation (energy, drive), executive function (inhibitory control, salience attribution, decision making), mood (stress reactivity and hedonic state), and interoception (internal awareness). This review focuses on the findings derived from brain-imaging.
studies with special attention to studies targeting DA pathways because these have been most widely investigated.

**DRUG REWARD IN ADDICTION**

In humans, several drugs [stimulants (12, 13), nicotine (14), alcohol (15, 16) and marijuana (17)] increase DA in the dorsal and ventral striatum. These studies are based on the measurement of DA D2 receptors that are not occupied by DA (receptor availability) and thus able to bind the PET radiotracers (i.e., [11C]raclopride, [18F]fallypride, or [11C]PHNO). By comparing D2/3 receptor availability after placebo and after acute drug exposures, these studies estimate the relative changes in DA (18). Most drugs tested in humans have shown a significant increase in DA in the ventral striatum (where the NAc is located) that was associated with the subjective perception of the drugs as rewarding (reviewed in Reference 19).

In addition, PET studies have shown that the pharmacokinetic profiles of drugs are crucial for their reinforcing effects. In particular, the speed at which drugs enter the human brain is associated with its rewarding effects. By labeling various drugs with positron emitters, it has been possible to monitor their pharmacokinetics in the human brain. These studies have shown that, after intravenous administration, nicotine reaches peak levels in 2–3 min, cocaine in 4–6 min, and methamphetamine in 10–15 min. In addition, at least for stimulant drugs, the fast drug uptake is associated with the “high” described by drug users (Figure 1) (20, 21). The various routes of drug administration (oral, smoked, injected) influence the speed at which drugs are delivered into the brain, which in turn affects their rewarding effects. For example, when cocaine enters the brain rapidly (smoked or intravenous administration) it elicits a more intense “high” than when it enters the brain more slowly (snorted) even when the cocaine doses given to participants are adjusted to produce the same levels of DA transporter blockade in the brain, which is the mechanism by which cocaine increases DA and produces reward (22). The dependence of drugs’ rewarding effects on their ability to induce “fast” and large DA increases probably reflects the fact that it mimics the fast and large DA increases associated with phasic DA firing that are associated in the brain with conveying information about reward and saliency (23).

Functional MRI (fMRI) is a noninvasive technique that allows us to monitor changes in brain physiology that are based on the increase in arterial blood flow to the local vasculature that accompanies neural activation. Because oxygenated hemoglobin (arterial blood) produces a different magnetic signal than that produced by deoxygenated hemoglobin (venous blood), this is the basis of the BOLD (blood-oxygen-level dependence) contrast used to track changes in regional brain activity at rest or upon stimulation. Imaging studies with fMRI to assess the activation/deactivation responses of the human brain to acute drug administration have reported that in cocaine abusers acute administration of cocaine induced deactivation of the ventral striatum (negative BOLD) that correlated with the high (24). In addition, such studies also reported a negative correlation with BOLD signals in the inferior frontal and orbitofrontal cortex as well as the anterior cingulate cortex (ACC), whereas craving correlated positively with activity in these regions. It is interesting to note that most fMRI studies evaluating the effects of stimulant drugs on reward report a deactivation of BOLD signals in the NAc rather than BOLD increases as may have been expected by activation of this brain region. In contrast, increases in BOLD are associated with craving (25). The deactivation of the NAc by cocaine is consistent with studies in nonhuman primates that also show inhibition of the NAc with cocaine administration, which were interpreted to reflect the predominance of D2R (inhibit cyclic AMP) over D1R (increase cyclic AMP) in the NAc (26). One important aspect to consider in fMRI studies assessing the effects of acute cocaine is that for ethical reasons these cannot be done in non-drug-abusing controls. Thus, it is not possible to determine
Figure 1
Pharmacokinetics of cocaine and methamphetamine in the human brain and relationship to the drug-induced “high.” (a) Axial brain images of the distribution of $^{11}$C)cocaine and $^{11}$C)methamphetamine at different times (minutes) after their administration. (b) Time activity curves for the concentration of $^{11}$C)cocaine and $^{11}$C)methamphetamine in striatum alongside the temporal course for the “high” experienced after intravenous administration of these drugs. Modified from References 20 and 21. Note that the fast brain uptake of these drugs corresponds with the temporal course of the “high,” which suggests that the “high” is associated with the “rate of dopamine increases.”
if the BOLD responses in the NAc reflect the pharmacological effects of cocaine or, alternatively, the adaptations associated with repeated drug use that in turn alter subsequent responses to the drug. This is because stimuli (including drugs) that induce fast and large DA increases also trigger conditioned responses, as a result of which the conditioned stimuli can increase DA (27).

Indeed, through conditioning, a neutral stimulus that is linked with the reinforcer (in this case, the drug) acquires the ability—on its own—to increase DA in the NAc in anticipation of the reward, and preclinical studies have shown that this effect is associated with drug-seeking behaviors (27). When exposed to a conditioned stimulus, the DA neurons in animals trained to expect a natural reinforcer (e.g., food) stop responding to the primary reinforcer and instead respond to the conditioned stimulus (23). These studies have also shown that, when the reward is expected and does not occur, DA cell firing is inhibited and DA release in the NAc is decreased. Thus, at this time, we cannot rule out the possibility that the decreases in BOLD detected through fMRI studies in the NAc of cocaine abusers after intravenous cocaine administration could reflect a decreased deactivation as a response to a drug whose effects are not as intense as may have been expected.

To answer this question, studies have compared the ability of stimulant drugs [methylphenidate (MPH) and amphetamine (AMPH)] to increase DA in the striatum of addicted versus nonaddicted subjects. Similar to cocaine, MPH increases DA by blocking DA transporters, whereas AMPH (similar to methamphetamine) increases DA by releasing it from the terminal using the DA transporter as carrier. Intravenous injection of these stimulant drugs is highly rewarding, and cocaine abusers report the effects to be similar to those of intravenous cocaine. Cocaine-addicted but detoxified subjects show marked attenuation of DA increases in the striatum induced by MPH or AMPH (at least 50% lower) and an attenuation of their self-reported “high,” when compared with non-drug-abusing controls (20, 28). Moreover, a more recent study provides the first comparison of responses to intravenous MPH in actively using cocaine abusers and showed that in these subjects MPH effects on striatal DA could not be distinguished from placebo (29). A comparison with the responses of the non-drug-abusing controls revealed the striatal DA changes in the cocaine abusers were 80% lower than in controls (Figure 2). Marked blunting of striatal DA increases to MPH and to AMPH have also been reported in detoxified alcoholics (reviewed in Reference 19).

The attenuated (or abolished) DA increases in response to stimulant drugs in cocaine addiction is paradoxical because cocaine-induced DA increases are linked to its rewarding effects, a finding that had led to the hypothesis of a sensitized response to the DA-enhancing effects of drugs (enhanced reward) that drove the exaggerated motivation to procure the drug in addiction. Similarly, the deactivation of the NAc after intravenous cocaine use suggests that these responses are adaptations that follow repeated drug administration (some related to tolerance but others to conditioning) rather than being a result of only the pharmacological effects of the drug.

**CONDITIONING IN ADDICTION**

Conditioning is one of the initial neuroadaptations that follows exposure to drugs and involves DA phasic signaling (predominantly though activation of D1R) and synaptic changes in NMDA and AMPA receptors (30, 31). These conditioned responses are believed to underlie the intense desire for the drug that occurs when addicted subjects are exposed to drug cues and that triggers their compulsive use of the drug.

Brain imaging studies to assess DA responses to conditioned cues have shown that active cocaine abusers exhibit significant DA increases in the striatum when they are exposed to videos depicting scenes of individuals procuring and administering cocaine. In addition, the magnitude of this increase was correlated with the subjective experience of craving (32, 33). Cocaine abusers with the largest cue-induced DA increases in the dorsal striatum also scored higher on addiction
Figure 2

Dopamine (DA) changes induced by intravenous methylphenidate (MPH) in controls and in active cocaine abusers and by cocaine cues in active cocaine abusers. (a) Average nondisplaceable binding potential (BP_{ND}) images of $[^{11}C]$raclopride in active cocaine-addicted subjects and controls tested after placebo and after intravenous MPH. MPH reduced D2R availability in controls but not in cocaine-addicted subjects. Note that cocaine abusers show both decreases in baseline striatal D2R availability (placebo measure) and decreases in DA release when given intravenous MPH (measured as decreases in D2R availability from baseline). (b) Average BP_{ND} images of $[^{11}C]$raclopride in cocaine abusers tested while viewing a neutral video (nature scenes) and while viewing a cocaine-cues video (subjects administering cocaine). The cocaine cues decreased D2R in caudate and putamen. Modified from Reference 32. Note that cocaine-addicted subjects did not respond to intravenous MPH but instead responded to the cocaine-cues exposure.

Thus, in active cocaine abusers, the DA increases triggered by conditioned cues appear to be larger than those produced by intravenous MPH. Moreover, the DA increases triggered by the severity, thereby suggesting that a basic disruption in addiction may be enhanced reactivity of DA mesostriatal pathways to conditioned responses. The dorsal striatum is implicated in habit learning; thus, its engagement with cue exposures is likely to reflect the strengthening of habits as chronicity of addiction progresses.
cues are associated with a desire for the drug, which suggests that conditioned responses may drive the DA signaling that triggers and maintains the motivation to take the drug. Indeed, fMRI studies of exposure to drug cues have consistently shown activation of the NAc with exposure to drug cues, which contrasts with studies in which subjects were administered cocaine and investigators reported decreases in BOLD signals in the NAc (25).

Nonetheless, regardless of the extent to which the drug (even when its DA-enhancing effects are attenuated) predicts reward, the act of its administration (injection, smoke, drink) becomes a conditioned cue so that the mere expectation of the reward during administration of the drug may increase DA in the NAc. On the basis of these findings and given the role of DA in predicting reward, we postulate a shift in the source of DA increases: Although drugs may initially lead to DA release in the NAc (i.e., signaling reward), with repeated administration and as habits develop, the DA increases become transferred from the pharmacological effects of the drug to the conditioned responses (i.e., to the behaviors and objects linked with administering the drugs, such as the act of injecting or seeing a syringe). Such an effect is reported to occur also with repeated exposure to natural reinforcers (23).

Brain imaging studies have shown that cue-elicited craving is associated not only with increased activation of the NAc (34–36), but also with activation of other reward regions including the VTA, orbitofrontal cortex, insula, and ACC (37–40). This suggests that processing of conditioned responses in the brain (as well as processing of reward) is the result of functional networks that include cortical and subcortical brain regions rather than involvement of isolated brain regional effects. Indeed, preclinical studies have revealed that glutamatergic projections from the prefrontal cortex (PFC) into the VTA/SN, NAc, and dorsal striatum as well as projections from the amygdala to the NAc are involved in these conditioned responses (10).

EXECUTIVE FUNCTION AND CORTICOSTRIATAL CIRCUITS IN ADDICTION

Imaging studies have been providing consistent evidence for the involvement of the PFC in the addiction process (41). In parallel, preclinical and clinical research has expanded our understanding of the complex role that the various regions in the PFC play in cognition. These identify a prominent role for the PFC in executive function that includes inhibitory control, decision making, emotional regulation, purposefulness, motivation, and salience attribution, among others. This explains why PFC disruption in addiction can have such catastrophic consequences across a wide range of behaviors (34).

The PFC works in tandem with striatal regions via corticostriatal networks that are modulated by DA (42). Imaging studies have documented disruption of these complex pathways, which have been investigated predominantly for the D2R-mediated signaling pathways and to a limited extent for the D1R-signaling pathway. In addicted subjects (to various drug classes including cocaine, heroin, alcohol, methamphetamine, nicotine, cannabinoids), a consistent finding reported from PET studies and corroborated by preclinical studies of chronic drug administration is that of significant reductions in D2R availability in the striatum, which persists months after detoxification (reviewed in Reference 19). Brain imaging studies on the effects of chronic drugs on D1R are few, and results are not always consistent. Specifically, in studies with nonhuman primates that were chronically exposed to cocaine, some investigators reported increases in D1R (43, 44), whereas others reported decreases (45). The conflicting reports suggest that the availability of D1R could be very sensitive to the characteristics (e.g., dosage, duration, frequency, and abstinence periods) of cocaine administration (46). In humans, imaging (PET) studies of cocaine abusers reported
Brain imaging studies have shown that reductions in striatal D2R in addicted subjects are associated with decreases in the activity of several prefrontal regions (Figure 3). These include the orbitofrontal cortex (involved in salience attribution and goal-directed behaviors), ACC (involved in inhibitory control and awareness), and the dorsolateral PFC (involved in higher cognitive operations and decision making) (35, 36, 48). Thus, improper DA modulation of these prefrontal regions in addicted subjects could underlie the enhanced incentive motivational value of drugs and the users’ loss of control over drug intake (41). Because impairments in the orbitofrontal cortex and ACC are associated with compulsive behaviors and impulsivity, we also postulate that DA’s impaired modulation of these regions could underlie the compulsive and impulsive drug taking in addiction (49, 50). Indeed, preclinical and clinical studies have shown that low striatal D2R levels are associated with impulsivity (51, 52), and in rodents, impulsivity predicts compulsive cocaine administration. In turn, overexpression of D2R in the striatum interferes with compulsive alcohol (53) and cocaine (54) intake. Imaging studies have also documented that in addicted subjects there are no changes in D1R (46), and postmortem studies of cocaine abusers and alcoholics reported no changes in D1R protein or mRNA (47).
is a decrease in DA release in the striatal regions (55) that is likely to further exacerbate an already low signaling from the reduced striatal D2R levels, which exert an inhibitory role on drug reward (56).

The fundamental role of the PFC in addiction is evidenced by the increased recognition that impairments in executive function may increase the vulnerability for a substance-use disorder. Thus, it is possible that in some addicted subjects the underlying vulnerability to drugs was triggered by impairments in PFC function and that subsequent repeated drug use led to decreases in striatal D2R. Evidence for this comes from a study of subjects at high risk for alcoholism: These subjects, who were not alcoholics but had a family history of alcoholism, exhibited a higher than normal striatal D2R availability that was associated with normal metabolism in the orbitofrontal cortex, ACC, and dorsolateral PFC (34). We interpreted this to suggest that the upregulation of striatal D2R allowed these high-risk individuals to maintain adequate prefrontal function, which protected them against alcohol abuse.

Impaired self-control plays a fundamental role in drug-taking behaviors in addiction. Successful self-regulation functions requires top-down control from the PFC to the striatal and limbic regions involved with rewards and emotions (reviewed in Reference 57). Impaired self-control in addicted subjects is believed to reflect disrupted prefrontal regulation of striatal regions. The level of impairment is influenced by the emotional state (negative mood increases impairment) and the context (exposure to unexpected cues can also impair it). Indeed, in cocaine abusers, cognitive control of craving is associated with decreased activation of the NAc and the orbitofrontal cortex, which is dependent on proper activity of the inferior PFC (BA 44) (58) (Figure 4). Moreover, lateral PFC activity assessed in cigarette smokers performing an inhibitory task (an experimental proxy of the self-control needed against temptations or distractions) predicted their craving and smoking behavior over the subsequent three-week period (59).

Disrupted executive function is also implicated in the exaggerated bias toward immediate smaller rewards at the expense of larger delayed ones that occurs in addiction (60). Specifically, damage of the orbitofrontal cortex in humans (61) and in rodents (62) increases the tendency to choose immediate rewards over larger delayed rewards. This is likely to contribute to addicted...
subjects’ tendency to choose the immediate gratification expected from taking the drug over any greater but delayed gratification that could be derived from staying sober.

Damage to the orbitofrontal cortex also interferes with the inhibition of responding to formerly rewarding cues that are no longer reinforcing, thus favoring the emergence of perseverative behaviors even when these are no longer reinforcing (reviewed in Reference 63). Thus, the dysregulated activity of the orbitofrontal cortex could underlie both the impulsive choices for immediate rewards and compulsive drug intake even when the drug-induced DA increases may be profoundly attenuated in addicted subjects (as described above).

MOTIVATION FOR DRUG REINFORCERS IN ADDICTION

DA plays a critical role in motivation (e.g., vigor, persistence, effort, behavioral activation) through its regulation of several target regions including the NAc, ACC, orbitofrontal cortex, dorsolateral PFC, amygdala, dorsal striatum, and ventral pallidum. Specifically, DA is implicated in the motivation costs required to complete tasks that demand high levels of effort (64). Mesolimbic DA signaling may energize goal seeking and influence cost-benefit evaluation in behavioral decisions (65).

The enhanced motivation to procure drugs is a hallmark of addiction, and this is well captured on the “incentive salience” hypothesis of addiction. This hypothesis proposes that, in addiction, drugs acquire enhanced “incentive salience” whereupon the drugs are consumed, not because they are liked (hedonic value), but because they are “wanted” (incentive value of reward) (66). In fact, the decrease in subjective responses to drugs along with the reduced drug-induced increases in DA support the notion that the motivation to procure drugs is not driven by drug “liking” but rather by an enhanced motivational drive to procure them. Indeed, drug-addicted individuals will go to extreme behaviors to obtain drugs even at the expense of seriously adverse consequences (2). In an addicted person, drug seeking and drug taking become the main motivational drives displacing all other activities (67). As a result, the addicted person is aroused and motivated when seeking to procure the drug and lacks motivation to pursue non-drug-related activities.

Brain imaging studies have monitored the shifts in regional brain activity of addicted persons when exposed to drug-conditioned cues versus when exposed to non-drug-related cues. When studied without exposure to drug stimuli, substance abusers showed significant decreases in activity of prefrontal regions implicated in motivation including the orbitofrontal cortex and ACC (reviewed in Reference 19). In contrast, these prefrontal regions become activated when drug abusers were exposed to drug-related stimuli (39, 68–70). Similarly, cocaine abusers studied shortly after an episode of cocaine binging showed increased metabolic activity in the orbitofrontal cortex and ACC (as well as the dorsal striatum), which was associated with drug craving (71).

The enhanced sensitivity of the motivational circuitry to drugs in addicted subjects is exemplified by a study by Volkow et al. (72): Whereas cocaine-addicted subjects exposed to a stimulant drug showed increased metabolism in the ventral ACC and medial orbitofrontal cortex (an effect that was associated with craving for the administered drug), nonaddicted subjects exposed to the same drug had decreased metabolism in these regions. This suggests that activation of these prefrontal regions with drug exposure may be specific to addiction and associated with the enhanced desire for the drug.

The modulation of motivation by drug cues in addiction may occur even outside of conscious awareness. Indeed, in cocaine abusers, exposure to subliminal cocaine cues induced activation of striatal and limbic brain regions (73). Moreover, these activation patterns predicted the affective responses to stimuli that were subsequently presented to subjects in a way that was visible to them. Overall, these imaging findings corroborate the involvement of the orbitofrontal cortex, ACC, and striatum (including the NAc) in the enhanced motivational value of drug stimuli in addiction.
and provide evidence for the involvement of unconscious processes in shaping motivation for drugs.

**MOOD AND STRESS REACTIVITY IN ADDICTION**

Negative emotions including those triggered by exposure to stressful stimuli provide an important prompt in drug taking. This may reflect the adverse effects that negative emotions have on self-control (57). Indeed, an imaging study in cocaine abusers assessed the effects of distressing stimuli and showed that such stimuli decreased activity in prefrontal regions while increasing it in striatal regions (74). In these subjects, the activation of striatal regions was associated with stress-induced cocaine craving and is consistent with a decrease in top-down control upon exposure to stressful stimuli.

The neurobiological mechanisms underlying the enhanced reactivity to negative emotions including those triggered by stressful stimuli have not been thoroughly investigated in human subjects. Preclinical studies suggest that these involve the CRF and noradrenergic systems that modulate stress reactivity (75) as well as an upregulated kappa opioid receptor signaling in the brain (76). Recent studies also suggest that the lateral habenula may be involved in drug relapse in addiction (77), including relapses triggered by negative emotionality and stress. The lateral habenula is neuroanatomically connected to circuits involved with reward and emotion (78). In nonhuman primates, neurons in the lateral habenula are inhibited by reward-predicting stimuli and activated by aversive-predicting stimuli or by unrewarded trials (79). Given that activation of the lateral habenula inhibits DA neurons in the VTA and the substantia nigra (79), this could be a mechanism that triggers drug use to compensate for the reduced DA signaling following DA-induced cell inhibition.

The lateral habenula also projects to the median and dorsal raphe nuclei, which contain serotonin neurons and regulate emotions (80). In addition, electrical stimulation of the lateral habenula inhibits serotonin neurons (81), which is consistent with a role for this anatomical structure in depression and anxiety (82). Thus, the lateral habenula, which is activated by aversive stimuli (including stress) (83) and linked with negative emotions and whose activation is further linked with drug relapse could be involved in mechanisms underlying the high relapse rate linked with negative mood and/or stress exposures. There are no reported imaging studies on the habenula in addiction, which is likely to reflect in part the small size of this brain region, which makes it difficult to image.

**SELF-AWARENESS IN ADDICTION**

In addiction, there is also evidence of a significant disruption in self-awareness, which includes the ability to recognize internal mental states (emotions, desires, and personal representation of one’s abilities). This is likely to impair an addicted individual’s awareness of disease, his/her need for treatment, and/or his/her strong desire for the drug (84). The neurocircuitry underlying self-awareness is not completely understood, but the default mode network (DMN) has been implicated in this process (85). The DMN includes regions from the dorsal and ventral ACC, insula, precuneus, and parietal cortex that become deactivated when performing a task but are active when mind-wandering (86, 87). Regions from the DMN that have been directly associated with impaired awareness in addiction include both the ACC and the insula.

**SUMMARY**

Several brain circuits are relevant in the neurobiology of addiction and result in an enhanced motivational value of the drug (secondary to learned associations through conditioning and habits).
at the expense of other reinforcers (secondary to decreased sensitivity of the reward circuit) and an impaired ability to inhibit the intentional actions associated with the strong desires to take the drug (secondary to impaired executive function) that result in compulsive drug taking in addiction (67). In addition, disrupted executive function contributes to impaired insight in addiction, which interferes with the recognition of disease and the need for treatment. Because these neuronal systems also play fundamental roles in social behaviors (88), understanding their disruption in addiction is providing insight into why drugs can be so disruptive to social relationships and why the typical positive reinforcers used to promote positive behaviors (e.g., pay increases, promotion) or the typical negative reinforcers used to deter negative behaviors (e.g., incarceration, fines) are by themselves ineffective in stopping drug use in addicted subjects (89). This model suggests a multipronged therapeutic approach to addiction designed to strengthen the neuronal systems that become disrupted in addiction.

**DISCLOSURE STATEMENT**

The authors are not aware of any affiliations, memberships, funding, or financial holdings that might be perceived as affecting the objectivity of this review.

**ACKNOWLEDGMENT**

We thank Ruben Baler for editorial assistance.

**LITERATURE CITED**


Contents

Silver Spoons and Other Personal Reflections
Alfred G. Gilman ................................................................. 1

Using Genome-Wide Association Studies to Identify Genes Important in Serious Adverse Drug Reactions
Ann K. Daly ................................................................. 21

Xenobiotic Metabolomics: Major Impact on the Metabolome
Caroline H. Johnson, Andrew D. Patterson, Jeffrey R. Idle, and Frank J. Gonzalez .... 37

Chemical Genetics–Based Target Identification in Drug Discovery
Feng Cong, Atwood K. Cheung, and Shib-Min A. Huang ............................................ 57

Old Versus New Oral Anticoagulants: Focus on Pharmacology
Jawed Fareed, Indermohan Thethi, and Debra Hoppensteadt .......................... 79

Adaptive Trial Designs
Tze Leung Lai, Philip William Lavori, and Mei-Chiung Shib ........................................ 101

Chronic Pain States: Pharmacological Strategies to Restore Diminished Inhibitory Spinal Pain Control
Hanns Ulrich Zeilhofer, Dietmar Benke, and Gonzalo E. Yevenes ............................ 111

The Expression and Function of Organic Anion Transporting Polypeptides in Normal Tissues and in Cancer
Amanda Obaidat, Megan Roth, and Bruno Hagenbuch ............................................ 135

The Best of Both Worlds? Bitopic Orthosteric/Allosteric Ligands of G Protein–Coupled Receptors
Celine Valant, J. Robert Lane, Patrick M. Sexton, and Arthur Christopoulos .......... 153

Molecular Mechanism of β-Arrestin-Biased Agonism at Seven-Transmembrane Receptors
Eric Reiter, Seungkirl Ahn, Arun K. Shukla, and Robert J. Lefkowitz ....................... 179

Therapeutic Targeting of the Interleukin-6 Receptor
Tosio Tanaka, Masashi Narazaki, and Tadamitsu Kishimoto .................................. 199
The Chemical Biology of Naphthoquinones and Its Environmental Implications
Yoshito Kumagai, Yasuhiro Shinkai, Takashi Miura, and Arthur K. Cho 221

Drug Transporters in Drug Efficacy and Toxicity
M.K. DeGorter, C.Q. Xia, J.J. Yang, and R.B. Kim 249

Adherence to Medications: Insights Arising from Studies on the Unreliable Link Between Prescribed and Actual Drug Dosing Histories
Terrence F. Blaschke, Lars Osterberg, Bernard Vrijens, and John Urquhart 275

Therapeutic Potential for HDAC Inhibitors in the Heart
Timothy A. McKinsey 303

Addiction Circuitry in the Human Brain
Nora D. Volkow, Gene-Jack Wang, Joanna S. Fowler, and Dardo Tomasi 321

Emerging Themes and Therapeutic Prospects for Anti-Infective Peptides
Nannette Y. Yount and Michael R. Yeaman 337

Novel Computational Approaches to Polypharmacology as a Means to Define Responses to Individual Drugs
Lei Xie, Li Xie, Sarah L. Kinnsings, and Philip E. Bourne 361

AMPK and mTOR in Cellular Energy Homeostasis and Drug Targets
Ken Inoki, Jyounghok Kim, and Kun-Liang Guan 381

Drug Hypersensitivity and Human Leukocyte Antigens of the Major Histocompatibility Complex
Mandvi Bharadwaj, Patricia Illing, Alex Theodossis, Anthony W. Purcell, Jamie Rossjohn, and James McCluskey 401

Systematic Approaches to Toxicology in the Zebrafish
Randall T. Peterson and Calum A. MacRae 433

Perinatal Environmental Exposures Affect Mammary Development, Function, and Cancer Risk in Adulthood
Suzanne E. Fenton, Casey Reed, and Retba R. Newbold 455

Factors Controlling Nanoparticle Pharmacokinetics: An Integrated Analysis and Perspective
S.M. Moghimi, A.C. Hunter, and T.L. Andresen 481

Systems Pharmacology: Network Analysis to Identify Multiscale Mechanisms of Drug Action
Shan Zhao and Ravi Iyengar 505
Integrative Continuum: Accelerating Therapeutic Advances in Rare Autoimmune Diseases
Katja Van Herle, Jacinta M. Bebne, Andre Van Herle, Terrence F. Blaschke, Terry J. Smith, and Michael R. Yeaman .................................................. 523

Exploiting the Cancer Genome: Strategies for the Discovery and Clinical Development of Targeted Molecular Therapeutics
Timothy A. Yap and Paul Workman .................................................. 549

Indexes
Contributing Authors, Volumes 48–52 .................................................. 575
Chapter Titles, Volumes 48–52 .............................................................. 578

Errata
An online log of corrections to Annual Review of Pharmacology and Toxicology articles may be found at http://pharmtox.annualreviews.org/errata.shtml